Relay Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 8, 2023 and accepted by EDGAR at Aug 8, 2023, 16:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $119.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $345.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$106.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$207.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$98.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$192.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.81 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$1.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.81 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$1.59 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$135.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $3.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $145.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $884.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $962.0m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $71.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $151.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $810.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-039874. Last ingested by Listed: Oct 30, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.